Skip to main content

Published locations for Sorafenib plus GCLAM held safe in AML, MDS phase-1 study

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Sorafenib plus GCLAM held safe in AML, MDS phase-1 study

User login

  • Reset your password
  • /content/sorafenib-plus-gclam-held-safe-aml-mds-phase-1-study
  • /hematologynews/article/199291/leukemia-myelodysplasia-transplantation/sorafenib-plus-gclam-held-safe
  • /oncologypractice/article/199291/leukemia-myelodysplasia-transplantation/sorafenib-plus-gclam-held
  • /hematology-oncology/article/199291/leukemia-myelodysplasia-transplantation/sorafenib-plus-gclam-held
  • /hematologytimes/article/199291/leukemia-myelodysplasia-transplantation/sorafenib-plus-gclam-held